Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence

This publication has 113 references indexed in Scilit:

• Pemphigoid diseases
  The Lancet, 2013
• A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation
  Diabetes, 2012
• Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database
  British Journal of Clinical Pharmacology, 2011
• Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
  Diabetes Care, 2011
• PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice
  Biological Chemistry, 2011
• Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
  Trends in Pharmacological Sciences, 2009
• Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study
  BMJ, 2008
• DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis
  Frontiers in Bioscience-Landmark, 2008
• Dual Inhibition of Dipeptidyl Peptidase IV and Aminopeptidase N Suppresses Inflammatory Immune Responses
  Annals of the New York Academy of Sciences, 2007
• Functional role of CD26 on human B lymphocytes
  Immunology Letters, 1995